Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindica
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... -- In the latest call for gender equity in ... 60 doctors and leading medical experts from across the ... and Drug Administration,s (FDA) decision to approve 26 drugs ... dysfunction compared with ZERO for women,s most common complaint, ... by approving the first-ever drug to treat Hypoactive Sexual ...
(Date:8/1/2014)... , August 1, 2014 ... Market by Type (Traditional Wound Closure, Anti infective), Basic ... (Artificial Skin & Skin Substitutes), Pressure Relief Devices, ... MarketsandMarkets, the global Wound Care Market is expected to ... in 2014, growing at a CAGR of 3.2% ...
(Date:8/1/2014)... PLYMOUTH MEETING, Pa. , Aug. 1, 2014 /PRNewswire/ ... that it will host a conference call to report ... 11, 2014 at 9:00 AM ET. CEO Dr. ... will discuss second quarter earnings, provide a corporate ... The update will include clinical development plans for VGX-3100, ...
Breaking Medicine Technology:60+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3
... division of Advanstar Communications, is pleased to announce the ... Reporting Congress. The industry acclaimed event takes place March ... Philadelphia, PA. Learn the latest strategies for revenue recognition, ... This is the largest assembly to date with over ...
Belgium, United Kingdom, Austria and The Netherlands. The DORC companies employ about 300 people. Visit our website : http://www.dorc.nl  ...
Cached Medicine Technology:Complete Agenda Announced for Pharma/Biotech Accounting and Reporting Congress 2
(Date:8/1/2014)... 01, 2014 As AndroGel lawsuits and ... Ronald E. Johnson, Jr. has been appointed as co-lead ... other testosterone medications. Since the Fall of 2013, Ron ... worked diligently to investigate and prosecute the claims of ... blood clots as a result of taking testosterone. As ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Growing ... coverage and healthcare reforms are boosting healthcare market ... medicines through discounts and increasing generic consumption is ... approximately 76.7 million in 2013, having grown at ... from 2008. The implementation of the Health Transformation ...
(Date:8/1/2014)... The "Antimicrobial Coatings Market by Type (Silver, Copper, ... and Zinc Omadine), Application (Indoor air/HVAC, Medical, Mold ... and others), & Geography (North America, Europe, Asia-Pacific, ... 2018" analyzes the Antimicrobial Coatings Market with respect ... diverse geographical regions. , Browse 49 market data ...
(Date:8/1/2014)... According to new market research report "Automotive ... Europe, & ROW), by Vehicle Type (Passenger Cars, ... Diesel), by After-Treatment Device (DPF, DOC, SCR, TWC, ... 2019", defines and segments the global automotive exhaust ... in all the regions, and estimates their exhaust ...
(Date:8/1/2014)... August 1, 2014 The Cardiovascular Research ... first report investigations that will be presented at ... symposium. TCT, the world,s premier educational meeting specializing ... 13 17, 2014 at the Walter E. ... research data presented at TCT often direct the ...
Breaking Medicine News(10 mins):Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 2Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 3Health News:Antimicrobial Coatings Market Projected to Reach $2.9 Billion by 2018 – Report by MarketsandMarkets 4Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4
... France's best-loved cheeses is in question after the two biggest ... untreated "raw" milk -- stopped production, citing health risks ... Lactalis and the Isigny Cooperative -- who together supplied 90 ... northwest region of Normandy -- have switched to using treated ...
... billion dollars) over the next eight years to the global ... to be published Thursday. ,Heidemarie Wieczorek-Zeul told ... to send a message to other member states during the ... Heiligendamm. ,"My appeal goes out to the other ...
... Hong Kong teenagers vibrates to the latest dance hit as a ... ,"Scream louder if you want more," a DJ shouts ... low-cut jeans throws his female partner onto his lap in a ... typical Friday night, but while many of the clubbers hail from ...
... Finnish Research study has found that exposure even a small ... serious and harmful impact on the cardiovascular system of a ... smoke can harm the childs arteries. ,Instead of relying ... the Finnish researchers used high-resolution ultrasound to check brachial artery ...
... old resident in New York, drank Boost Plus, a vitamin enriched ... ,When he woke up the next day, he had ... for medical advice and for treatment of the condition called severe ... is persistent, painful erection of the penis. Recurrent or severe episodes ...
... that the prison population in England and Wales reached a ... there were fewer than 300 cells available for new inmates. ... to house prisoners in some areas of the country. ... the BMAs Civil and Public Services Committee said: ...
Cached Medicine News:Health News:Fate of France's Cheeses in Doubt as Producers Cite Health Risks 2Health News:Fate of France's Cheeses in Doubt as Producers Cite Health Risks 3Health News:Drugs Lure Hong Kong Youth Across China Border 2Health News:Drugs Lure Hong Kong Youth Across China Border 3Health News:Prison Healthcare Under Strain as Overcrowding Crisis Worsens, Warns BMA 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: